NHS Hot Flushes: HRT Alternative Treatment Options

For the estimated 500,000 women in England for whom Hormone Replacement Therapy (HRT) isn’t an option, a significant new treatment pathway has just opened. The National Institute for Health and Care Excellence (NICE) has recommended Veoza (fezolinetant), a non-hormonal drug, for managing moderate to severe menopausal hot flushes and night sweats. This isn’t simply about adding another drug to the formulary; it represents a crucial shift towards addressing a long-neglected gap in care for a substantial portion of the menopausal population.

The menopause, and the perimenopause leading up to it, is increasingly recognized not just as a biological event, but as a significant public health issue. Falling estrogen levels trigger a cascade of symptoms impacting sleep, concentration, emotional wellbeing, and even professional performance. While HRT remains the first-line treatment – and is expected to continue to be for the majority – its contraindications and patient hesitancy (often fueled by historical misinformation) leave a considerable number of women seeking alternative solutions. Historically, these options have been limited, often involving off-label use of antidepressants or other medications with less targeted effects.

Veoza’s approval follows its initial authorization in 2023, but the NICE recommendation is the critical step for NHS access. The drug works by blocking neurokinin 3 (NK3) receptors in the brain, which play a key role in regulating body temperature. Clinical trials have demonstrated a significant reduction in the frequency and severity of hot flushes and night sweats compared to placebo. Importantly, NICE highlighted the drug’s cost-effectiveness as a key factor in its decision, signaling a willingness to invest in innovative solutions for women’s health when value is demonstrated.

The Forward Look

The immediate impact will be increased access to a much-needed treatment option for eligible women in England. However, several key developments are likely to unfold. First, we can anticipate similar reviews and potential approvals in Wales, Northern Ireland, and Scotland, though timelines will vary given their independent healthcare decision-making bodies. Second, the real-world effectiveness of Veoza will be closely monitored. Post-market surveillance will be crucial to identify any rare side effects or long-term impacts not detected in clinical trials.

Perhaps the most significant long-term implication is the potential for Veoza to destigmatize the search for non-hormonal menopause solutions. For years, the conversation has largely centered on HRT, sometimes to the exclusion of other valid approaches. The availability of a NICE-approved, targeted therapy could empower women to have more informed discussions with their healthcare providers and explore a wider range of personalized treatment options. Finally, pharmaceutical companies will undoubtedly be encouraged to invest further in research and development of novel non-hormonal therapies, potentially leading to even more effective and tailored solutions for managing the diverse challenges of menopause in the future.

It’s important to note the stated contraindications: Veoza is not suitable for women with breast cancer, other oestrogen-dependent cancers, or liver disease. Individual assessments will be necessary to determine suitability, particularly for women with a history of breast cancer who have completed treatment.